Compare AbCellera Biologics Inc (ABCL) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Tyson Foods, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.93 (market cap $2.99B), while Tyson Foods, Inc. trades at $56 (market cap $19.85B). The key difference: Tyson Foods, Inc. is far larger — about 6.6× AbCellera Biologics Inc's market cap, and Tyson Foods, Inc. pays a 3.62% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TSN | |
|---|---|---|
Market Cap | $2.99B | $19.85B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $68.75 |
52-Week Low | $2.78 | $50.72 |
Enterprise Value | $2.58B | $27.12B |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
Tyson Foods (TSN) trades at $55.85, down 2.29% today, reflecting bearish technical signals and mixed fundamentals. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue missed expectations amid declining volumes. The company faces headwinds from persistent losses in its beef segment, though chicken and prepared foods remain profitable. Analyst consensus is a 'Buy' with a $68.50 price target, suggesting significant upside potential from current levels.
The outlook hinges on Tyson's ability to stabilize beef margins while leveraging strength in other segments. Investment appeal lies in its low P/S ratio of 0.36 and dividend yield, but risks include volatile commodity costs and execution challenges. Near-term performance will depend on Q3 2026 results and management's guidance update.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
